Skip to content

Study · Non-randomized trial · n = 13 · 1999

5 results

Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.

Orskov L, Nyholm B, Yde Hove K, Gravholt CH, Møller N, Schmitz O

Diabetic medicine : a journal of the British Diabetic Association1 Oct 1999Cited by 11 (Europe PMC)

PMID10547215 (opens in a new tab)DOI10.1046/j.1464-5491.1999.00162.x (opens in a new tab)PepBankPUB-10547215
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In men with type 1 diabetes, baseline endogenous glucose production was similar after pramlintide and placebo.

    In plain wordsIn men with type 1 diabetes, baseline glucose production was similar after pramlintide and placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeBaseline endogenous glucose production
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg q.i.d. · subcutaneous · 4 weeksAs given in this study (human).

    Measurements

    Baseline endogenous glucose production
    1.32 mg x kg(-1). min(-1)
    first value of vs. pair, +/-0.22; group order not labelled in source
    Baseline endogenous glucose production
    1.2 mg x kg(-1). min(-1)
    second value of vs. pair, +/-0.13; group order not labelled in source

    Source sentences

    Summary
    Baseline plasma glucose (5.59+/-0.16 vs. 5.67+/-0.25 mmol/l) and endogenous glucose production (EGP) (1.32+/-0.22 vs. 1.20+/-0.13 mg x kg(-1). min(-1)) were similar
    1 context sentence
    Summary · context
    Thirteen Type 1 diabetic men were studied in a double-blind, placebo-controlled, cross-over study after 4 weeks of subcutaneous pramlintide (30 microg q.i.d.) or placebo administration.
  2. 02HumanNon-randomized trialEfficacy outcome

    In men with type 1 diabetes, pramlintide did not change glucose responses to the glucagon challenge versus placebo.

    In plain wordsIn men with type 1 diabetes, glucose responses to glucagon were unchanged with pramlintide compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeGlucose response to glucagon
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg q.i.d. · subcutaneous · 4 weeksAs given in this study (human).

    Measurements

    Plasma glucose during glucagon step 1
    6.01 mmol/l
    pramlintide, +/-0.31
    Plasma glucose during glucagon step 1
    5.94 mmol/l
    placebo, +/-0.38
    Plasma glucose during glucagon step 2
    6 mmol/l
    pramlintide, +/-0.37
    Plasma glucose during glucagon step 2
    5.96 mmol/l
    placebo, +/-0.50

    Source sentences

    Summary
    and the response to glucagon was unaffected by pramlintide (glucose: step 1; 6.01+/-0.31 vs. 5.94+/-0.38 mmol/l, step 2; 6.00+/-0.37 vs. 5.96+/-0.50 mmol/l, EGP:
    1 context sentence
    Summary · context
    Thirteen Type 1 diabetic men were studied in a double-blind, placebo-controlled, cross-over study after 4 weeks of subcutaneous pramlintide (30 microg q.i.d.) or placebo administration.
  3. 03HumanNon-randomized trialEfficacy outcome

    In men with type 1 diabetes, pramlintide did not change endogenous glucose production responses to glucagon versus placebo.

    In plain wordsIn men with type 1 diabetes, glucose production responses to glucagon were unchanged with pramlintide compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeEndogenous glucose production response to glucagon
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg q.i.d. · subcutaneous · 4 weeksAs given in this study (human).

    Measurements

    Endogenous glucose production during glucagon step 1
    1.91 mg x kg(-1) x min(-1)
    pramlintide, +/-0.18
    Endogenous glucose production during glucagon step 1
    1.83 mg x kg(-1) x min(-1)
    placebo, +/-0.15
    Endogenous glucose production during glucagon step 2
    2.08 ng x kg(-1) x min(-1)
    pramlintide, +/-0.17; unit as printed in source
    Endogenous glucose production during glucagon step 2
    1.96 ng x kg(-1) x min(-1)
    placebo, +/-0.16; unit as printed in source

    Source sentences

    Summary
    EGP: step 1; 1.91+/-0.18 vs. 1.83+/-0.15 mg x kg(-1) x min(-1), step 2; 2.08+/-0.17 vs. 1.96+/-0.16 ng x kg(-1) x min(-1), pramlintide vs. placebo).
    1 context sentence
    Summary · context
    Thirteen Type 1 diabetic men were studied in a double-blind, placebo-controlled, cross-over study after 4 weeks of subcutaneous pramlintide (30 microg q.i.d.) or placebo administration.
  4. 04HumanNon-randomized trialEfficacy outcome

    In men with type 1 diabetes, glucose disposal at baseline was similar after pramlintide and placebo.

    In plain wordsIn men with type 1 diabetes, baseline glucose disposal was similar after pramlintide and placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeBaseline glucose disposal
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg q.i.d. · subcutaneous · 4 weeksAs given in this study (human).

    Measurements

    Baseline glucose disposal rate
    2.44 mg x kg(-1) x min(-1)
    pramlintide, +/-0.13
    Baseline glucose disposal rate
    2.28 mg x kg(-1) x min(-1)
    placebo, +/-0.09

    Source sentences

    Summary
    Glucose disposal rates were similar at baseline (2.44+/-0.13 vs. 2.28+/-0.09 mg x kg(-1) x min(-1), pramlintide vs. placebo) as well as during the glucagon challenge (P-values all > 0.2).
    1 context sentence
    Summary · context
    Thirteen Type 1 diabetic men were studied in a double-blind, placebo-controlled, cross-over study after 4 weeks of subcutaneous pramlintide (30 microg q.i.d.) or placebo administration.
  5. 05HumanNon-randomized trialEfficacy outcome

    In men with type 1 diabetes, glucose disposal during glucagon challenge was similar after pramlintide and placebo.

    In plain wordsIn men with type 1 diabetes, glucose disposal during glucagon challenge was similar after pramlintide and placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeGlucose disposal during glucagon challenge
    Study

    n = 13

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 microg q.i.d. · subcutaneous · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Glucose disposal rates were similar at baseline (2.44+/-0.13 vs. 2.28+/-0.09 mg x kg(-1) x min(-1), pramlintide vs. placebo) as well as during the glucagon challenge (P-values all > 0.2).
    1 context sentence
    Summary · context
    Thirteen Type 1 diabetic men were studied in a double-blind, placebo-controlled, cross-over study after 4 weeks of subcutaneous pramlintide (30 microg q.i.d.) or placebo administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.